MOESM4 of Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma

Lang, Liwei; Shay, Chloe; Zhao, Xiangdong; Xiong, Yuanping; Wang, Xuli; Teng, Yong

doi:10.6084/m9.figshare.11329139.v1

13045_2019_827_MOESM4_ESM.docx (95.95 kB)

MOESM4 of Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma

journal contribution

posted on 2019-12-06, 04:44 authored by Liwei Lang, Chloe Shay, Xiangdong Zhao, Yuanping Xiong, Xuli Wang, Yong Teng

Additional file 4: Figure S4. The average weight of tongue and body in HN8- (A) and HN12-derived orthotopic xenograft mice (B) during different treatments. *p<0.05; **p<0.01.

Funding

National Institute of Dental and Craniofacial Research

History

Usage metrics

Keywords

HNSCC Src, AKT Saracatinib Capivasertib Co-delivery nanoparticles Synergistic effects

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

MOESM4 of Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma

Funding

National Institute of Dental and Craniofacial Research

History

Usage metrics

Categories

Keywords

Licence

Exports